论文部分内容阅读
目的评价血清ＣＡ１２５，ＣＡ１９９，ＣＡ５０含量对消化系肿瘤的诊断价值．方法消化系肿瘤患者１５８例，其中肝癌３８例，食管癌２１例，胃癌５６例，结直肠癌３６例，胰腺癌７例；消化系良性疾病患者１０６例，其中肝硬变５７例，消化性溃疡４９例；正常对照者４０例．全部受测对象均空腹抽静脉血，分离血清，－２０℃贮存备测．采用ＲＩＡ法测定血清ＣＡ１２５，ＣＡ１９９，ＣＡ５０含量，使用国产ＳＮ６９５型γ计数仪．数据均用ｘ±ｓ表示，以正常ｘ±２ｓ作为上限计算阳性率．结果肝癌、胃癌、胰腺癌、结直肠癌和食管癌血清（ＣＡ含量均以ｋＵ／Ｌ表达）ＣＡ１２５（分别为２２２±１１６，７９±１７，１３５±７９，６９±２３和７２±２６），ＣＡ１９９（２３７±１０８，２８１±１３２，８３８±２２４，２５２±１３６和２７３±１４６）和ＣＡ５０含量（２５±９，２０±７，１８±９，１８±８和１７±７）显著高于正常对照组及消化道良性病变组（Ｐ＜００１）．消化道肿瘤有腹腔及远处转移者，其血清ＣＡ１２５，ＣＡ１９９，ＣＡ５０含量升高更为明显．结论血清ＣＡ１２５，ＣＡ１９９，ＣＡ５０均为较好的肿瘤标记物，有助于诊断消化系统肿瘤
Objective To evaluate the diagnostic value of serum CA125, CA19 9, CA50 in digestive system tumors. Methods There were 158 patients with digestive tumors, including 38 cases of liver cancer, 21 cases of esophageal cancer, 56 cases of gastric cancer, 36 cases of colorectal cancer, 7 cases of pancreatic cancer, 106 cases of benign diseases of the digestive system, 57 cases of cirrhosis, and digestive diseases. 49 cases of ulcers; 40 cases of normal controls. All subjects were fasted venous blood, serum was separated, stored at -20 °C for testing. The serum levels of CA125, CA19 9, and CA50 were determined by RIA and the domestic SN695 gamma counter was used. The data are expressed as x±s, and the positive rate is calculated using the normal x±2s as the upper limit. Results Serum levels of CA125 were detected in hepatoma, gastric cancer, pancreatic cancer, colorectal cancer, and esophageal cancer (CA levels were expressed as kU/L) (222±116, 79±17, 135±79, 69±23, and 72±26, respectively). CA19-9 (237±108,281±132,838±224,252±136 and 273±146) and CA50 content (25±9,20±7,18±9,18±8 and 17±7) were significantly higher In the normal control group and benign gastrointestinal disease group (P <0 01). Gastrointestinal tumors have abdominal cavity and distant metastases, and their serum CA125, CA19 9, CA50 levels increase more significantly. Conclusion Serum CA125, CA199, and CA50 are good tumor markers and are helpful for the diagnosis of digestive system tumors.